Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia
The Efficacy and Safety of Fluoroscopic-Guided Bipolar Versus Monopolar Pulsed Radiofrequency for Refractory Trigeminal Neuralgia: An Exploratory Study
1 other identifier
interventional
20
1 country
2
Brief Summary
A prospective exploratory study aiming at comparing pulsed bipolar versus pulsed unipolar radiofrequency ablation in patients with medically refractory trigeminal neuralgia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2024
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
January 13, 2025
CompletedFirst Posted
Study publicly available on registry
January 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedJanuary 17, 2025
January 1, 2025
1.4 years
January 13, 2025
January 16, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Numerical pain scale (NRS)
50% Pain reduction in the numerical rating scale (NRS)
Two weeks, 1 month, 3 months, and 6 months
Secondary Outcomes (1)
Adverse events monitoring (Frequency, severity, seriousness, and causality)
6 months
Study Arms (2)
Monopolar pulsed radiofrequncy
PLACEBO COMPARATORPatients with refractory TN undergoing monopolar pulsed radiofrequency
Bipolar pulsed radiofrequency
ACTIVE COMPARATORPatients with refractory TN undergoing bipolar pulsed radiofrequency
Interventions
Bipolar pulsed radiofrequency ablation: the active comparator
Monopolar pulsed radiofrequency ablation: the placebo
Eligibility Criteria
You may qualify if:
- Patients with a definitive diagnosis of classical TN based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Either purely paroxysmal classical TN or classical TN with concomitant chronic pain.
- Patients with idiopathic TN, with symptomatic clinical topography of V2 and/or V3.
- Patients with brain magnetic resonance imaging (MRI) unremarkable for structural etiology for the trigeminal pain.
- Patients with medically refractory TN defined as pain persisting beyond three months at a level of ≥5/10 after monotherapy or polytherapy in appropriate medical doses.
You may not qualify if:
- Painful trigeminal neuropathy based on the third version of the International Classification of Headache Disorders (ICHD-3).
- Trigeminal neuralgia with V1 symptomatic clinical topography.
- Trigeminal neuralgia comorbid with other atypical facial pain disorders.
- Structural TN e.g., due to vascular compression, posterior fossa tumors, central demyelination, …etc.
- Patients exposed to previous radiofrequency procedures, as this may impair the nerve response to current PRF.
- Patients who refused to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Alexandria University Faculty of Medicine
Alexandria, 21517, Egypt
Cairo University Kasr Alainy Faculty of Medicine
Cairo, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer in Neurology
Study Record Dates
First Submitted
January 13, 2025
First Posted
January 16, 2025
Study Start
January 1, 2024
Primary Completion
June 1, 2025
Study Completion
September 1, 2025
Last Updated
January 17, 2025
Record last verified: 2025-01